CD274 and meningioma: Due to the emerging evidence on PD-L1 expression in recurrent meningiomas, there are several ongoing trials investigating the anti-PD1 antibodies nivolumab, avelumab, or pembrolizumab in WHO grade 3 or recurrent meningiomas [57].